September 10, 2025Oncology and TherapyOpen Access

Progression-Free Survival Under Immune Checkpoint Inhibitors for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Cohort Study

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective cohort identifies biomarkers predicting progression-free survival in metastatic NSCLC, suggesting refined patient selection.

Median progression-free survival for patients with lung metastases reached 11.7 months, highlighting prognostic differences.
Five independent prognostic biomarkers were identified, including smoking status, lung metastases, and neutrophil-to-lymphocyte ratio.
Average samples involved included 173 and 253 patients treated with nivolumab across two distinct cohorts.
The nomogram-based prediction model was validated and demonstrated distinct prognostic groups based on rwPFS.

Boré et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective cohort identifies biomarkers predicting progression-free survival in metastatic NSCLC, suggesting refined patient selection.